Adjunct Professor, Department of Medicine
Jay D Kranzler, MD, PhD has been a Founder, CEO, Board Member, and Advisor to leading life science companies for over 30 years. He is currently acting as Chief Executive Officer of Regenovation, a regenerative medicine company, and is a Board Member of Regenovation, Methylation Sciences, Pastorus, Avenue Pharmaceuticals, and ImmunoBrain Checkpoint, and provides consulting services to multiple large pharmaceutical companies, small biotechnology companies, investment banks, and investors.
Dr. Kranzler has experience consulting to, as well as leading both small biotechnology companies as well as major pharmaceutical companies. After graduating from Yale University School of Medicine with MD and PhD degrees with a focus in psychopharmacology, Dr. Kranzler joined McKinsey & Company where he established the Firm’s pharmaceutical practice, before becoming the Chief Executive Officer of Cytel Corporation, a company focused on the development of immunomodulatory drugs. He took Cytel public, and negotiated partnerships with both global and Japanese pharmaceutical companies that set new standards for deal size and structure. After Cytel, Dr. Kranzler became Chief Executive Officer of Cypress Bioscience (formerly IMRE Corporation) where he was credited for the development of Savella™ (milnacipran) for the treatment of fibromyalgia, and Karuna Pharmaceuticals, focusing on the treatment of Schizophrenia.
Dr. Kranzler joined Pfizer in April 2013, becoming Vice President, Head of External R&D Innovation Pharmatherapeutics and Strategic Investments, with responsibility for multiple therapeutic areas and technologies including Neuroscience, Pain, Rare Diseases, and Gene Therapy, as well as with developing and leading Pfizer’s R&Dnnovate Venture Fund.
In addition, Jay is the Founder and Principal of Jay D Kranzler Consulting, LLC, and advises multiple institutional investors as well as pharmaceutical and biotechnology companies. During his career, Dr. Kranzler has developed drugs, medical devices, as well as diagnostics, and is the inventor on over 30 patents. Dr. Kranzler received the Innovator award from the International Society of CNS Clinical Development, has been nominated twice as the “Entrepreneur of the Year” and is an Adjunct Professor, New York University Stern School of Business and School of Medicine, serves on The NYU Entrepreneurial Institute’s Advisory Board, and was an Executive in Residence at UCSD’s Rady School of Management.
MD from Yale University
PhD from Yale University
Journal of translational science. 2018 Apr; 4(2):
Neuropsychiatric disease & treatment. 2010 May 25; 6:197-208
Sleep & breathing = Schlaf & Atmung. 2009 May; 13(2):163-7
Journal of rheumatology. 2009 Feb; 36(2):398-409
Psychopharmacology bulletin. 2007 Feb; 40(4):24-67
Journal of rheumatology. 2005 Oct; 32(10):1975-85
Human psychopharmacology. 2004 Oct; 19 Suppl 1:S27-35